The FDA Just Gave 7 Companies a Backstage Pass to Drug Approval
The FDA selected seven companies for its first-ever PreCheck pilot, a program that lets the agency review drug factories while they're still being built. It could shave over a year off approval timelines and reshape how biotech thinks about manufacturing.
Think TSA PreCheck, but for Drug Factories
Imagine building a brand-new restaurant. You spend millions on the kitchen, hire a team, design the menu. Then the health inspector shows up on opening night and tells you the ventilation is wrong. You have to rip it out and start over. Months of delays. Customers gone.
That's essentially what happens in pharma manufacturing. Companies pour billions into new drug factories, then cross their fingers that the FDA won't find problems during the review of their drug application. When the agency does find issues (and it often does), the result is a Complete Response Letter: regulatory speak for "try again later."
The FDA just decided to fix that. On June 29, it selected seven companies for the inaugural cohort of its PreCheck Pilot Program, a new pathway that lets the agency review manufacturing facilities while they're still being built, not after the fact. Think of it like getting the health inspector involved when you're drawing up the blueprints, not when you're plating the first dish.
The Lucky Seven
More than 80 companies applied during a one-month window back in February. Only seven made the cut:
Eli Lilly (Lebanon, Indiana): making active pharmaceutical ingredients for current and future medicines
Regeneron (Saratoga Springs, New York): protein therapeutics, sterile injectables, and biologics
FUJIFILM Biotechnologies (Holly Springs, North Carolina): large-scale biologics manufacturing
Cellares (Bridgewater, New Jersey): cell-based gene therapies for cancer and blood diseases
Kriya Therapeutics (Durham, North Carolina): gene therapies for chronic diseases
Kyowa Kirin (Sanford, North Carolina): biotech manufacturing for rare diseases
Amneal Pharmaceutical (Long Island, New York): sterile liquid drugs for pain, respiratory, and eye conditions
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The mix is deliberate. FDA picked across modalities: small molecules, biologics, cell therapy, gene therapy. Big pharma (Lilly, Regeneron) sits alongside smaller platform companies (Cellares, Kriya). That sends a clear signal: this isn't a club for incumbents only.
How It Actually Works
PreCheck runs in two phases, and the structure is what makes it genuinely different from anything the FDA has tried before.
Phase 1 is all about facility readiness. Before a single pill is pressed or vial is filled, FDA scientists work directly with the company on facility design, equipment choices, quality systems, and operational plans. The company builds a specialized file (called a Drug Master File) that gives the FDA a detailed, continuously updated picture of the manufacturing site.
Phase 2 kicks in when the company is ready to submit its actual drug application (an NDA for small molecules, a BLA for biologics, or their equivalents). Because the FDA already knows the facility inside and out, the manufacturing review portion should be dramatically faster. Fewer surprises, fewer back-and-forth cycles, fewer delays.
The analogy that keeps coming up in regulatory circles is TSA PreCheck: vetted, lower-risk entities move through a streamlined lane, but the underlying security standards don't change. Nobody is lowering the bar. They're just moving the conversation earlier.
Why This Matters More Than You Think
Manufacturing problems are one of the most common causes of drug application delays. They trigger multi-cycle reviews that can add a year or more to the approval timeline. For a biotech company burning cash while waiting for revenue, that delay can be existential.
Some FDA estimates suggest PreCheck could save participating companies up to 14 months in certain cases. That's not just a nice-to-have; it's the difference between launching a drug while your patent clock is still ticking and watching competitors eat your lunch.
For investors, the implications are significant. Manufacturing risk has always been one of the hardest things to underwrite. How do you put a number on the chance that an FDA inspector finds something wrong with a $2 billion factory? PreCheck makes that risk more quantifiable by front-loading the FDA's feedback. Regulatory advisers are already framing it as a factor that could lower the cost of capital for greenfield manufacturing projects in the U.S.
The Bigger Game: Bringing Drug Manufacturing Home
PreCheck didn't emerge in a vacuum. It launched in February 2026 in direct response to an executive order on strengthening domestic drug manufacturing. The eligibility rules tell the story: only new U.S.-based facilities qualify. No existing sites, no overseas plants, no simple expansions.
The FDA even gave preference to companies sourcing their raw materials domestically. The message is unmistakable: if you want the regulatory fast lane, build it in America.
For U.S.-based contract manufacturers (CDMOs), this is a potential goldmine. A CDMO that's been through PreCheck can tell biotech clients, "Our facility is already FDA-vetted." That's a powerful selling point, especially for small biotechs that can't afford to build their own plants. Analysts expect PreCheck-certified facilities to become a competitive advantage in the contract manufacturing market.
What It Can't Do (Yet)
Before anyone gets too excited, some caveats. PreCheck is a pilot. Seven companies. New facilities only. If you're upgrading an existing plant or transferring production from one site to another, you're out of luck.
That's actually the industry's biggest complaint. A lot of practical capacity gains could come from modernizing existing sites, not just building shiny new ones. Regulatory commentators have flagged this as the most important unresolved question: will the FDA eventually extend PreCheck concepts to existing facilities and technology transfers?
The agency says it will use lessons from this first cohort to "further enhance the program" for future rounds. Translation: they're testing the plumbing before they open the floodgates.
The Scorecard
PreCheck sits alongside a flurry of other FDA modernization pilots in 2026, including AI-powered one-day inspections (46 completed so far), a National Priority Voucher program that aims to cut review times from 10–12 months to 1–2 months, and a real-time clinical trials initiative. Taken together, they represent the most aggressive push to modernize FDA processes in a generation.
But PreCheck is unique because it attacks a problem that's been hiding in plain sight: the disconnect between when companies build factories and when the FDA actually looks at them. By closing that gap, the program could fundamentally change how biotech companies plan, finance, and execute their manufacturing strategies.
Seven companies just got a head start. The rest of the industry is watching very closely.
Clinical & Regulatory
4 min read
The FDA Fired Thousands of People. Now It's Hiring 2,200 Back.
The FDA slashed 3,000 workers last year. Now it's scrambling to hire 2,200 back, but the math still doesn't add up. Here's what it means for drug approvals, biotech timelines, and whether the regulatory engine can survive the whiplash.
